Nanotechnology Now - News Story: START chosen to test drug compound that suppresses cancer-causing genes

Home > News > START chosen to test drug compound that suppresses cancer-causing genes

March 13th, 2008

START chosen to test drug compound that suppresses cancer-causing genes

Abstract:
South Texas Accelerated Research Therapeutics (START) has been selected as one of two clinics that will conduct Phase I trials for an anti-cancer compound developed by Calando Pharmaceuticals.

Calando also submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration to initiate the clinical trial for the drug, CALAA-01.

The drug is a targeted nanoparticle designed to activate the body's natural mechanism to "silence" the "inappropriate activity" of specific genes causing cancer. The trial will evaluate whether CALAA-01 is safe and tolerable by humans. Anthony Tolcher, M.D., director of clinical research at START, will be leading the study in San Antonio.

START is a partnership that directs clinical trials of novel anticancer agents and is headquartered at San Antonio's South Texas Medical Center. The group is constructing a new 120,000-square-foot office headquarters building, scheduled to open in July 2008.

Source:
bizjournals.com

Bookmark: